Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study

[1] McInnes IB(2011)The pathogenesis of rheumatoid arthritis N Engl J Med 365 2205-2219

[2] Schett G(2016)Rheumatoid arthritis Lancet 388 2023-2038

[3] Smolen JS(2006)Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2793-2806

[4] Aletaha D(2001)Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines J Immunol 167 6015-6020

[5] McInnes IB(2005)The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models Arthritis Res Ther 7 29-37

[6] Cohen SB(2004)Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol Cell Biol 82 1-9

[7] Emery P(2004)Interleukin-17: a mediator of inflammatory responses Cell Mol Life Sci 61 567-579

[8] Greenwald MW(2003)Interleukin-17 family and IL-17 receptors Cytokine Growth Factor Rev 14 155-174

[9] Dougados M(2014)Secukinumab in plaque psoriasis–results of two phase 3 trials N Engl J Med 371 326-338

[10] Furie RA(2015)Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 386 1137-1146

[1] McInnes IB(2011)The pathogenesis of rheumatoid arthritis N Engl J Med 365 2205-2219

[2] Schett G(2016)Rheumatoid arthritis Lancet 388 2023-2038

[3] Smolen JS(2006)Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2793-2806

[4] Aletaha D(2001)Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines J Immunol 167 6015-6020

[5] McInnes IB(2005)The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models Arthritis Res Ther 7 29-37

[6] Cohen SB(2004)Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol Cell Biol 82 1-9

[7] Emery P(2004)Interleukin-17: a mediator of inflammatory responses Cell Mol Life Sci 61 567-579

[8] Greenwald MW(2003)Interleukin-17 family and IL-17 receptors Cytokine Growth Factor Rev 14 155-174

[9] Dougados M(2014)Secukinumab in plaque psoriasis–results of two phase 3 trials N Engl J Med 371 326-338

[10] Furie RA(2015)Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 386 1137-1146